Autolus Therapeutics plc
AUTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $600 | $1,120 | $180 | $374 |
| - Cash | $227 | $240 | $382 | $310 |
| + Debt | $297 | $53 | $24 | $21 |
| Enterprise Value | $669 | $934 | -$178 | $85 |
| Revenue | $10 | $2 | $6 | $2 |
| % Growth | 496% | -72.6% | 311% | – |
| Gross Profit | -$131 | $2 | $6 | $2 |
| % Margin | -1,293.5% | 100% | 100% | 100% |
| EBITDA | -$233 | -$157 | -$132 | -$132 |
| % Margin | -2,303.1% | -9,232.6% | -2,135% | -8,790.6% |
| Net Income | -$221 | -$208 | -$149 | -$142 |
| % Margin | -2,180.5% | -12,272.3% | -2,403% | -9,429.1% |
| EPS Diluted | -0.87 | -1.2 | -1.57 | -1.97 |
| % Growth | 27.5% | 23.6% | 20.3% | – |
| Operating Cash Flow | -$206 | -$146 | -$112 | -$118 |
| Capital Expenditures | -$35 | -$11 | -$11 | -$9 |
| Free Cash Flow | -$241 | -$157 | -$123 | -$127 |